Els
Els Blazejczak, Landen BE
Patent application number | Description | Published |
---|---|---|
20130323949 | RELEASE TAB FOR AN ELECTRICAL CONNECTOR AND ELECTRICAL CONNECTOR COMPRISING SAID RELASE TAB - The present invention relates to a release tab ( | 12-05-2013 |
Els Festjens, Zwevegem BE
Patent application number | Description | Published |
---|---|---|
20120148607 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 06-14-2012 |
20140205606 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 07-24-2014 |
20150376291 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 12-31-2015 |
20150376292 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 12-31-2015 |
Els Festjens, Zwevegen BE
Patent application number | Description | Published |
---|---|---|
20120156206 | C-MET ANTIBODY COMBINATIONS - The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein. | 06-21-2012 |
Els Fieremans, New York, NY US
Patent application number | Description | Published |
---|---|---|
20120002851 | System, Method and Computer Accessible Medium for Providing Real-Time Diffusional Kurtosis Imaging and for Facilitating Estimation of Tensors and Tensor- Derived Measures in Diffusional Kurtosis Imaging - Exemplary method, system, and computer-accessible medium can be provided for determining a measure of diffusional kurtosis by receiving data relating to at least one diffusion weighted image, and determining a measure of a diffusional kurtosis as a function of the received data using a closed form solution procedure. In accordance with certain exemplary embodiments of the present disclosure, provided herein are computer-accessible medium, systems and methods for, e.g., imaging in an MRI system, and, more particularly for facilitating estimation of tensors and tensor-derived measures in diffusional kurtosis imaging (DKI). For example, DKI can facilitate a characterization of non-Gaussian diffusion of water molecules in biological tissues. The diffusion and kurtosis tensors parameterizing the DKI model can typically be estimated via unconstrained least squares (LS) methods. In the presence of noise, motion, and imaging artifacts, these methods can be prone to producing physically and/or biologically implausible tensor estimates. The exemplary embodiments of the present disclosure can address at least this deficiency by formulating an exemplary estimation problem, e.g., as linearly constrained linear LS, where the constraints can ensure acceptable tensor estimates. | 01-05-2012 |
20120095700 | SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR DETERMINING MEMBRANE PROPERTIES RELATING TO DIFFUSION - Exemplary embodiments of a methodology, procedure, system, method and computer-accessible medium can be provided to obtain particular information relating to at least one transport property of a material containing at least one membrane, and to determine, e.g., a permeability of the membrane of the material and/or a surface area of the membrane of the material, as a function of, e.g., the obtained particular information. | 04-19-2012 |
20140314298 | SYSTEM, METHOD AND COMPUTER ACCESSIBLE MEDIUMS OR DETERMINING NEURODEGENERATION - Method, system and computer-accessible medium for determining at least one of axonal loss or myelin degradation can be provided. For example, it is possible to receive data based on at least one of a measure of diffusion of an axonal structure or a measure of a density of axons, and determine axonal loss and/or myelin degradation based on the data. The determination can be based on axonal geometry of at least one parallel tube. | 10-23-2014 |
20150055845 | System, Method and Computer Accessible Medium for Providing Real-Time Diffusional Kurtosis Imaging and for Facilitating Estimation of Tensors and Tensor- Derived Measures in Diffusional Kurtosis Imaging - Exemplary method, system, and computer-accessible medium can be provided for determining a measure of diffusional kurtosis by receiving data relating to at least one diffusion weighted image, and determining a measure of a diffusional kurtosis as a function of the received data using a closed form solution procedure. In accordance with certain exemplary embodiments of the present disclosure, provided herein are computer-accessible medium, systems and methods for, e.g., imaging in an MRI system, and, more particularly for facilitating estimation of tensors and tensor-derived measures in diffusional kurtosis imaging (DKI). For example, DKI can facilitate a characterization of non-Gaussian diffusion of water molecules in biological tissues. The diffusion and kurtosis tensors parameterizing the DKI model can typically be estimated via unconstrained least squares (LS) methods. In the presence of noise, motion, and imaging artifacts, these methods can be prone to producing physically and/or biologically implausible tensor estimates. The exemplary embodiments of the present disclosure can address at least this deficiency by formulating an exemplary estimation problem, e.g., as linearly constrained linear LS, where the constraints can ensure acceptable tensor estimates. | 02-26-2015 |
Els Henckaerts, New York, NY US
Patent application number | Description | Published |
---|---|---|
20090300782 | Targeted gene addition in stem cells - The present invention provides methods for adenoassociated virus-mediated site-specific integration of a transgene into a stem cell. Stem cells having a transgene integrated therein, and differentiated cells generated from the stem cells are also provided. | 12-03-2009 |
Els Kesters, Holsbeek BE
Patent application number | Description | Published |
---|---|---|
20100071718 | Method for Removing a Hardened Photoresist - A method for removing a hardened photoresist from a semiconductor substrate. An example method for removing a hardened photoresist layer from a substrate comprising a low-κ dielectric material preserving the characteristics of the low-k dielectric material includes: a)—providing a substrate comprising a hardened photoresist layer and a low-κ dielectric material at least partially exposed; b)—forming C═C double bonds in the hardened photoresist by exposing the hardened photoresist to UV radiation having a wavelength between 200 nm and 300 nm in vacuum or in an inert atmosphere; c)—breaking the C═C double bonds formed in step b) by reacting the hardened photoresist with ozone (O | 03-25-2010 |
Els Louagie, Torhout BE
Patent application number | Description | Published |
---|---|---|
20130273080 | SIALOADHESIN-RELATED COMPOSITIONS AND METHODS - Methods of delivering a cargo moiety to a cell is provided that include contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided herein. | 10-17-2013 |
Els Mannekens, Edegem BE
Patent application number | Description | Published |
---|---|---|
20160040352 | POLY-ELECTROLYTE POLYMER COMPOSITION AND ITS USE - A poly-electrolyte composition for forming a water insoluble copolymer suitable as a hydrogel, wherein the copolymer is formed by means of free radical polymerization of at least a first and a second hydrophilic monomer, wherein the first monomer is selected from vinylic sulphonic acids, vinylic phosphonic acids or a water soluble salt thereof, and wherein the second monomer is a vinylic monomer with an electron-withdrawing spacer between the double bond and an acidic group, at least one compound selected from the group consisting of monomers comprising an acidic group either in the free acid form or in the form of a water soluble salt, and of which the logarithm of the acid dissociation constant (pKa) in the free acid form has a value smaller than 3.5. | 02-11-2016 |
Els Marjaux, Attenrode-Wever BE
Patent application number | Description | Published |
---|---|---|
20110091446 | SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY - The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease. | 04-21-2011 |
20150071940 | SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY - Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease. | 03-12-2015 |
Els Vanbleu, Berlare BE
Patent application number | Description | Published |
---|---|---|
20130058890 | METHODS FOR CONTROLLING PESTS USING RNAi - The present invention concerns methods for controlling insect infestation via RNAi-mediated gene silencing, whereby the intact insect cell(s) are contacted with a double-stranded RNA from outside the insect cell(s) and whereby the double-stranded RNA is taken up by the intact insect cell(s). In one particular embodiment, the methods of the invention are used to alleviate plants from insect pests. Alternatively, the methods are used for treating and/or preventing insect infestation on a substrate or a subject in need of such treatment and/or prevention. Suitable insect target genes and fragments thereof, dsRNA constructs, recombinant constructs and compositions are disclosed. | 03-07-2013 |
20140373197 | DSRNA AS INSECT CONTROL AGENT - The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for making transgenic plants that express the double stranded RNA molecules, as well as pesticidal agents and commodity products produced by the inventive plants. | 12-18-2014 |
Els Vanbleu, Ieper BE
Patent application number | Description | Published |
---|---|---|
20090285784 | DSRNA As Insect Control Agent - The present invention concerns methods for controlling insect infestation via RNAi-mediated gene silencing, whereby the intact insect cell(s) are contacted with a double-stranded RNA from outside the insect cell(s) and whereby the double-stranded RNA is taken up by the intact insect cell(s). In one particular embodiment, the methods of the invention are used to alleviate plants from insect pests. Alternatively, the methods are used for treating and/or preventing insect infestation on a substrate or a subject in need of such treatment and/or prevention. Suitable insect target genes and fragments thereof, dsRNA constructs, recombinant constructs and compositions are disclosed. | 11-19-2009 |
20090298787 | Dsrna as Insect Control Agent - The present invention relates to methods for controlling pest infestation using double standard RNA molecules. The invention provides methods for making transgenic plants that express the double stranded RNA molecules, as well as pesticidal agents and commodity products produced by the inventive plants. | 12-03-2009 |
Els Van Bleu, Leper BE
Patent application number | Description | Published |
---|---|---|
20090306189 | Methods for Controlling Pests Using Rnai - The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules. | 12-10-2009 |
Els Van Bleu, Berlare BE
Patent application number | Description | Published |
---|---|---|
20150065557 | METHODS FOR CONTROLLING PESTS USING RNAi - The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules. | 03-05-2015 |
Els Van Bleu, Belare BE
Patent application number | Description | Published |
---|---|---|
20150128303 | TRANSGENIC PLANT-BASED METHODS FOR PLANT PESTS USING RNAI - The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for making transgenic plants that express the double stranded RNA molecules, as well as pesticidal agents and commodity products produced by the inventive plants. | 05-07-2015 |
Els Van Eetvelde, Brussels BE
Patent application number | Description | Published |
---|---|---|
20120214888 | PROCESS FOR PREPARING A POLYURETHANE FOAM - The invention relates to a process for preparing a polyurethane foam, wherein a polyether polyol and a polyisocyanate are reacted in the presence of: a blowing agent; of from 1 to 30 ppmw, based on the polyether polyol, of metals derived from a composite metal cyanide complex catalyst; and of from 0.5 to 100 ppmw, based on the polyether polyol, of a phosphoric acid compound comprising a phosphoric acid selected from orthophosphoric acid, polyphosphoric acid and polymetaphosphoric acid, and/or a partial ester of such a phosphoric acid. | 08-23-2012 |
Els Verhoeyen, Lyon FR
Patent application number | Description | Published |
---|---|---|
20100247497 | VECTOR PARTICLES FOR TARGETNG CD34+ CELLS - The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: —a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and —a second protein which comprises a ligand of the c-Kit receptor. | 09-30-2010 |
20140017792 | VECTOR PARTICLES FOR TARGETING CD34+ CELLS - The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: | 01-16-2014 |
20140235700 | LENTIVIRAL VECTORS PSEUDOTYPED WITH MUTANT BaEV GLYCOPROTEINS - The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:—a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or—a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide. | 08-21-2014 |